Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2014 1
2016 1
2017 1
2019 5
2020 6
2021 3
2022 9
2023 21
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, Ritter T, Baert F, Schreiber S, Sloan S, Cataldi F, Shan K, Rabbat CJ, Chiorean M, Wolf DC, Sands BE, D'Haens G, Danese S, Goetsch M, Feagan BG. Sandborn WJ, et al. Lancet. 2023 Apr 8;401(10383):1159-1171. doi: 10.1016/S0140-6736(23)00061-2. Epub 2023 Mar 2. Lancet. 2023. PMID: 36871574 Free article. Clinical Trial.
The full analysis set of ELEVATE UC 52 comprised 289 patients assigned to etrasimod and 144 to placebo. In ELEVATE UC 12, 238 patients were assigned to etrasimod and 116 to placebo. ...Adverse events were reported in 206 (71%) of 289 patients in the etrasimod …
The full analysis set of ELEVATE UC 52 comprised 289 patients assigned to etrasimod and 144 to placebo. In ELEVATE UC 12, 238 patient …
Etrasimod for the treatment of ulcerative colitis.
Wils P, Peyrin-Biroulet L. Wils P, et al. Immunotherapy. 2023 Apr;15(5):311-321. doi: 10.2217/imt-2022-0255. Epub 2023 Feb 15. Immunotherapy. 2023. PMID: 36789612 Review.
This article reviews the mechanism of action of etrasimod and summarizes the available clinical efficacy and safety data regarding etrasimod, which is a promising drug in the treatment of patients with moderate to severe ulcerative colitis. Etrasimod is a new …
This article reviews the mechanism of action of etrasimod and summarizes the available clinical efficacy and safety data regarding …
Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J. Sandborn WJ, et al. Gastroenterology. 2020 Feb;158(3):550-561. doi: 10.1053/j.gastro.2019.10.035. Epub 2019 Nov 9. Gastroenterology. 2020. PMID: 31711921 Free article. Clinical Trial.
BACKGROUND & AIMS: Etrasimod (APD334) is an oral, selective sphingosine 1-phosphate receptor modulator in development for immune-mediated inflammatory disorders. We assessed the efficacy and safety of etrasimod in patients with moderately to severely acti …
BACKGROUND & AIMS: Etrasimod (APD334) is an oral, selective sphingosine 1-phosphate receptor modulator in development for …
Emerging therapies for eosinophilic esophagitis.
Meek PD, Hemstreet B. Meek PD, et al. Pharmacotherapy. 2023 Apr;43(4):338-348. doi: 10.1002/phar.2783. Epub 2023 Mar 11. Pharmacotherapy. 2023. PMID: 36840634 Review.
Therapies targeting other key inflammatory mediators in EoE, such as Siglec-8 (lirentelimab), IL-13 (cendakimab), and the sphingosine 1-phosphate receptor (etrasimod) are currently being evaluated in clinical trials....
Therapies targeting other key inflammatory mediators in EoE, such as Siglec-8 (lirentelimab), IL-13 (cendakimab), and the sphingosine 1-phos …
Emerging drugs for the treatment of alopecia areata.
Ramírez-Marín HA, Tosti A. Ramírez-Marín HA, et al. Expert Opin Emerg Drugs. 2022 Dec;27(4):379-387. doi: 10.1080/14728214.2022.2149735. Epub 2022 Nov 21. Expert Opin Emerg Drugs. 2022. PMID: 36408593 Review.
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.
Pérez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Pérez-Jeldres T, et al. Drugs. 2021 Jun;81(9):985-1002. doi: 10.1007/s40265-021-01528-8. Epub 2021 May 13. Drugs. 2021. PMID: 33983615 Free PMC article. Review.
A clinical trial in patients with COVID-19 treated with ozanimod is ongoing. Ozanimod and etrasimod have shown promising results in IBD; while in phase 2 clinical trials, ponesimod has shown improvement in 77% of the patients with psoriasis. Cenerimod and amiselimod have b …
A clinical trial in patients with COVID-19 treated with ozanimod is ongoing. Ozanimod and etrasimod have shown promising results in I …
Etrasimod.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 38051804 Free Books & Documents. Review.
No information is available on the use of etrasimod during breastfeeding. Because etrasimod is 98% bound to plasma proteins, the amount in milk is likely to be low. If the mother requires etrasimod, it is not a reason to discontinue breastfeeding. Until more …
No information is available on the use of etrasimod during breastfeeding. Because etrasimod is 98% bound to plasma proteins, t …
Modulating sphingosine 1-phosphate receptor signaling skews intrahepatic leukocytes and attenuates murine nonalcoholic steatohepatitis.
Liao CY, Barrow F, Venkatesan N, Nakao Y, Mauer AS, Fredrickson G, Song MJ, Sehrawat TS, Dasgupta D, Graham RP, Revelo XS, Malhi H. Liao CY, et al. Front Immunol. 2023 Apr 21;14:1130184. doi: 10.3389/fimmu.2023.1130184. eCollection 2023. Front Immunol. 2023. PMID: 37153573 Free PMC article.
Alanine aminotransferase, a sensitive circulating marker for liver injury, was reduced in response to Etrasimod and Amiselimod treatment. Liver histology showed a reduction in inflammatory foci in Etrasimod-treated mice. ...Etrasimod treatment results in a su …
Alanine aminotransferase, a sensitive circulating marker for liver injury, was reduced in response to Etrasimod and Amiselimod treatm …
Etrasimod: First Approval.
Shirley M. Shirley M. Drugs. 2024 Feb;84(2):247-254. doi: 10.1007/s40265-024-01997-7. Drugs. 2024. PMID: 38388871 Review.
Etrasimod is selective for S1P receptor subtypes S1P(1), S1P(4) and S1P(5) while having minimal activity on S1P(3) and no activity on S1P(2). ...Etrasimod is also under regulatory review for the treatment of ulcerative colitis in several other countries. ...
Etrasimod is selective for S1P receptor subtypes S1P(1), S1P(4) and S1P(5) while having minimal activity on S1P(3) and no activity on …
Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.
Vermeire S, Chiorean M, Panés J, Peyrin-Biroulet L, Zhang J, Sands BE, Lazin K, Klassen P, Naik SU, Cabell CH, Sandborn WJ. Vermeire S, et al. J Crohns Colitis. 2021 Jun 22;15(6):950-959. doi: 10.1093/ecco-jcc/jjab016. J Crohns Colitis. 2021. PMID: 33475734 Free PMC article. Clinical Trial.
BACKGROUND AND AIMS: Etrasimod is an oral, selective, sphingosine 1-phosphate receptor modulator. ...This open-label extension [OLE] evaluated safety and efficacy of etrasimod for up to 52 weeks. METHODS: In OASIS, 156 patients received etrasimod 1 mg, etr …
BACKGROUND AND AIMS: Etrasimod is an oral, selective, sphingosine 1-phosphate receptor modulator. ...This open-label extension [OLE] …
57 results